SHL Telemedicine, a leading provider and developer of advanced personal telemedicine solutions, has announced a significant expansion of its offerings in Israel. For the first time in the world, users in Israel will have the ability to perform an at-home Biomarker blood test, guided by SHL's medical team, following ECG tests using The SmartHeart® for Rapid Heart Attack Detection.
This innovative diagnostic tool is set to revolutionize emergency cardiac care by enabling the rapid identification of cardiac markers for the detection of heart attacks. The addition of the Biomarker test provides a comprehensive snapshot, similar to an emergency room assessment, by combining this novel blood test with a detailed medical history (anamnesis) and a 12-lead ECG transmission. This trio of diagnostic elements, now all available from home through SHL Telemedicine, will aid in quickly identifying cardiac events during the critical symptomatic phase, potentially saving lives.
When a potential cardiac event is suspected, the Biomarker test is administered as the final step in the diagnosis process, following anamnesis and ECG broadcasting. SHL's telemedicine team guides the patient in real-time on how to perform the blood test and continues to provide support until emergency medical services arrive. The results from the Biomarker test are available within ten minutes, enabling swift action to be taken.
Erez Nachtomy, CEO of SHL Telemedicine, emphasized the significance of this advancement, stating, "The ability to perform at-home Biomarker blood tests in Israel is a significant advancement in our mission to revolutionize accessible cardiac care. This innovative approach not only speeds up the process of diagnosing heart attacks but also significantly enhances the safety and efficacy of at-home cardiac monitoring."
SHL Telemedicine is committed to developing and marketing personal telemedicine systems and providing medical call center services, with a focus on cardiovascular and related diseases. The company offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology.
NASDAQ: SHLT
Current Price: $10.25
Change: +8.47%
Based on the technical analysis model, SHL Telemedicine is currently in an uptrend. The stock price has been steadily increasing, indicating strong bullish sentiment in the market. The stock has found support at key levels and has managed to break through resistance points, suggesting further upside potential. The moving averages, particularly the 50-day and 200-day moving averages, are trending upwards, confirming the bullish momentum. The MACD (Moving Average Convergence Divergence) indicator has shown a bullish crossover, with the MACD line crossing above the signal line, indicating a positive trend. Fibonacci retracement levels suggest that the stock has the potential to reach higher levels, with the next resistance level identified at $11.50. The Bollinger Bands have been expanding, indicating increased volatility, which could lead to further price appreciation if the uptrend continues. Overall, the technical analysis suggests a positive outlook for SHL Telemedicine, with the stock exhibiting strong bullish momentum and the potential for further gains in the near term. The company's groundbreaking expansion of its offerings in Israel, including the at-home Biomarker blood test, is expected to drive investor interest and support the stock's upward trajectory.
